MDT

96.87

+0.54%↑

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

MDT

96.87

+0.54%↑

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

MDT

96.87

+0.54%↑

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

MDT

96.87

+0.54%↑

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

MDT

96.87

+0.54%↑

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Abierto

SectorSanidad

22.3 -0.84

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

22.08

Máximo

23.26

Métricas clave
By Trading Economics
Ingresos	675K 53M
Ventas	1.8M 148M
P/B Media del Sector	13.333 87.826
Margen de beneficios	35.57
Empleados	181
EBITDA	1.7M 80M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+50.44% upside

Dividendos
By Dow Jones
Próximas Ganancias	25 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	178M 2.8B
Apertura anterior	23.14
Cierre anterior	22.3

Noticias sobre sentimiento de mercado

By Acuity

50%

173 / 370 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 ene 2026, 23:54 UTC

Charlas de Mercado

CBA Could Underperform Again in 2026 -- Market Talk

12 ene 2026, 23:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen -- Market Talk

12 ene 2026, 23:43 UTC

Charlas de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 ene 2026, 23:18 UTC

Adquisiciones, fusiones, absorciones

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 ene 2026, 21:56 UTC

Charlas de Mercado

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

12 ene 2026, 21:18 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

12 ene 2026, 21:18 UTC

Charlas de Mercado

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 ene 2026, 20:54 UTC

Ganancias

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 ene 2026, 20:48 UTC

Charlas de Mercado

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 ene 2026, 20:33 UTC

Charlas de Mercado

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 ene 2026, 20:18 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 ene 2026, 20:18 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 ene 2026, 19:39 UTC

Charlas de Mercado

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 ene 2026, 19:36 UTC

Charlas de Mercado

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 ene 2026, 19:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 ene 2026, 19:33 UTC

Charlas de Mercado

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 ene 2026, 19:24 UTC

Adquisiciones, fusiones, absorciones

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 ene 2026, 19:22 UTC

Adquisiciones, fusiones, absorciones

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 ene 2026, 18:21 UTC

Adquisiciones, fusiones, absorciones

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 ene 2026, 18:20 UTC

Adquisiciones, fusiones, absorciones

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 ene 2026, 18:19 UTC

Charlas de Mercado

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 ene 2026, 18:16 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 ene 2026, 18:09 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

12 ene 2026, 18:09 UTC

Charlas de Mercado

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 ene 2026, 18:01 UTC

Adquisiciones, fusiones, absorciones

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 ene 2026, 18:00 UTC

Charlas de Mercado

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

50.44% repunte

Estimación a 12 Meses

Media 34 USD 50.44%

Máximo 35 USD

Mínimo 33 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

173 / 370 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.